Circadian Disruption Associated with Alzheimer’s Disease

Sleep (M Thorpy and M Billiard, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Sleep


Alzheimer’s disease (AD) is increasing in prevalence and has a significant impact on caregivers and the healthcare system. One of the many physiologic process affected by AD is the circadian system, with disruption reflected in abnormalities of the sleep-wake cycle. This interaction is bidirectional, with circadian and sleep disruption influencing disease progression. Understanding the bidirectional relationship between AD and circadian disruption may allow for earlier recognition of the potential to develop dementia as well as improved targeted approaches for therapy. Therapies including melatonin and bright light therapy may be advantageous in improving sleep and circadian rhythms and preventing the progression of disease. However, unfortunately, these modalities are not curative, and additional research is needed to improve treatment options for these individuals.


Alzheimer’s disease Circadian disruption β-Amyloid Melatonin Bright light therapy 


Compliance with Ethical Standards

Conflict of Interest

Yumna Saeed and Sabra M. Abbott declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer’s disease: current and emerging strategies. Nature and science of sleep. 2016;8:21–33.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778–83.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Pistacchi M, Gioulis M, Contin F, Sanson F, Marsala SZ. Sleep disturbance and cognitive disorder: epidemiological analysis in a cohort of 263 patients. Neurological Sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2014;35:1955–62.CrossRefGoogle Scholar
  4. 4.
    Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 2005;6:347–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Cipriani G, Lucetti C, Danti S, Nuti A. Sleep disturbances and dementia. Psychogeriatrics: the official journal of the Japanese Psychogeriatric Society. 2015;15:65–74.CrossRefGoogle Scholar
  6. 6.
    Hope T, Keene J, Gedling K, Fairburn CG, Jacoby R. Predictors of institutionalization for people with dementia living at home with a carer. International Journal of Geriatric Psychiatry. 1998;13:682–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer’s disease: focus on the role of hypocretin and melatonin. Ageing Res Rev. 2013;12:188–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, Reppert SM. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell. 1999;96:57–68.CrossRefPubMedGoogle Scholar
  9. 9.
    Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Cassone VM, Chesworth MJ, Armstrong SM. Entrainment of rat circadian rhythms by daily injection of melatonin depends upon the hypothalamic suprachiasmatic nuclei. Physiol Behav. 1986;36:1111–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson RF, Moore RY, Morin LP. Loss of entrainment and anatomical plasticity after lesions of the hamster retinohypothalamic tract. Brain Res. 1988;460:297–313.CrossRefPubMedGoogle Scholar
  12. 12.
    Mattis J, Sehgal A. Circadian rhythms, sleep, and disorders of aging. Trends in Endocrinology and Metabolism: TEM. 2016;27:192–203.CrossRefPubMedGoogle Scholar
  13. 13.
    Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet. 2004;5:407–41.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sherin JE, Shiromani PJ, McCarley RW, Saper CB. Activation of ventrolateral preoptic neurons during sleep. Science (New York, NY). 1996;271:216–9.CrossRefGoogle Scholar
  15. 15.
    de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95:322–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci Off J Soc Neurosci. 2005;25:6716–20.CrossRefGoogle Scholar
  17. 17.
    Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 2007;450:420–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci Off J Soc Neurosci. 2009;29:10939–49.CrossRefGoogle Scholar
  19. 19.
    Carter ME, Yizhar O, Chikahisa S, et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat Neurosci. 2010;13:1526–33.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci Off J Soc Neurosci. 1998;18:9996–10015.Google Scholar
  21. 21.
    Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Gerdin MJ, Masana MI, Rivera-Bermudez MA, et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology. 2004;18:1646–56.CrossRefGoogle Scholar
  23. 23.
    Tzischinsky O, Shlitner A, Lavie P. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. J Biol Rhythm. 1993;8:199–209.CrossRefGoogle Scholar
  24. 24.
    Hut RA, Van der Zee EA. The cholinergic system, circadian rhythmicity, and time memory. Behav Brain Res. 2011;221:466–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamakawa GR, Basu P, Cortese F, et al. The cholinergic forebrain arousal system acts directly on the circadian pacemaker. Proc Natl Acad Sci U S A. 2016;113:13498–503.CrossRefPubMedGoogle Scholar
  26. 26.
    Abbott SM, Arnold JM, Chang Q, et al. Signals from the brainstem sleep/wake centers regulate behavioral timing via the circadian clock. PLoS One. 2013;8:e70481.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology. 2014;71:505–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Abbott SM, Zee PC. Irregular sleep-wake rhythm disorder. Sleep medicine clinics. 2015;10:517–22.CrossRefPubMedGoogle Scholar
  29. 29.
    Merlino G, Piani A, Gigli GL, et al. Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 2010;11:372–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Craig LA, McDonald RJ. Chronic disruption of circadian rhythms impairs hippocampal memory in the rat. Brain Res Bull. 2008;76:141–51.CrossRefPubMedGoogle Scholar
  31. 31.
    Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol. 1999;58:29–39.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhou JN, Hofman MA, Swaab DF. VIP neurons in the human SCN in relation to sex, age, and Alzheimer’s disease. Neurobiol Aging. 1995;16:571–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985;342:37–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Wang JL, Lim AS, Chiang WY, et al. Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann Neurol. 2015;78:317–22.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Liu RY, Zhou JN, Hoogendijk WJ, et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol. 2000;59:314–22.CrossRefPubMedGoogle Scholar
  36. 36.
    Coogan AN, Schutova B, Husung S, et al. The circadian system in Alzheimer’s disease: disturbances, mechanisms, and opportunities. Biol Psychiatry. 2013;74:333–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Tate B, Aboody-Guterman KS, Morris AM, Walcott EC, Majocha RE, Marotta CA. Disruption of circadian regulation by brain grafts that overexpress Alzheimer beta/A4 amyloid. Proc Natl Acad Sci U S A. 1992;89:7090–4.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Song Q, Feng G, Huang Z, Chen X, Chen Z, Ping Y. Aberrant axonal arborization of PDF neurons induced by Abeta42-mediated JNK activation underlies sleep disturbance in an Alzheimer’s model. Mol Neurobiol. 2016.Google Scholar
  39. 39.
    Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurology. 2013;70:587–93.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. Nat Rev Neurol. 2014;10:115–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Spira AP, Gamaldo AA, An Y, et al. Self-reported sleep and beta-amyloid deposition in community-dwelling older adults. JAMA Neurology. 2013;70:1537–43.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Roh JH, Huang Y, Bero AW, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med. 2012;4:150ra122.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cyclee. Science (New York, NY) 2009; 326:1005–1007.Google Scholar
  44. 44.
    Selkoe DJ. The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann Neurol. 2013;74:328–36.CrossRefPubMedGoogle Scholar
  45. 45.
    Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch Neurol. 2012;69:51–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Tabuchi M, Lone SR, Liu S, et al. Sleep interacts with abeta to modulate intrinsic neuronal excitability. Current biology: CB. 2015;25:702–12.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47:e148.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron. 2003;37:925–37.CrossRefPubMedGoogle Scholar
  49. 49.
    Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750–6.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Nir Y, Staba RJ, Andrillon T, et al. Regional slow waves and spindles in human sleep. Neuron. 2011;70:153–69.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Martin PR, Loewenstein RJ, Kaye WH, Ebert MH, Weingartner H, Gillin JC. Sleep EEG in Korsakoff's psychosis and Alzheimer’s disease. Neurology. 1986;36:411–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Song H, Moon M, Choe HK, et al. Abeta-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer’s disease. Mol Neurodegener. 2015;10:13.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Varga AW, Wohlleber ME, Gimenez S, et al. Reduced slow-wave sleep is associated with high cerebrospinal fluid Abeta42 levels in cognitively normal elderly. Sleep. 2016;39:2041–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science (New York, NY). 2013;342:373–7.CrossRefGoogle Scholar
  56. 56.
    Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science (New York, NY). 1995;269:973–7.CrossRefGoogle Scholar
  57. 57.
    Belanger V, Picard N, Cermakian N. The circadian regulation of Presenilin-2 gene expression. Chronobiol Int. 2006;23:747–66.CrossRefPubMedGoogle Scholar
  58. 58.
    Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry. 1999;45:417–21.CrossRefPubMedGoogle Scholar
  59. 59.
    Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res. 2005;38:145–52.CrossRefPubMedGoogle Scholar
  60. 60.
    Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35:125–30.CrossRefPubMedGoogle Scholar
  61. 61.
    Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon 4/4 genotype. J Clin Endocrinol Metab. 1999;84:323–7.PubMedGoogle Scholar
  62. 62.
    Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer’s disease. Int J Mol Sci. 2013;14:14575–93.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Colwell CS, Kaufman CM, Menaker M. Phase-shifting mechanisms in the mammalian circadian system: new light on the carbachol paradox. J Neurosci Off J Soc Neurosci. 1993;13:1454–9.Google Scholar
  64. 64.
    Erhardt C, Galani R, Jeltsch H, et al. Modulation of photic resetting in rats by lesions of projections to the suprachiasmatic nuclei expressing p75 neurotrophin receptor. Eur J Neurosci. 2004;19:1773–88.CrossRefPubMedGoogle Scholar
  65. 65.
    Feng R, Li L, Yu H, Liu M, Zhao W. Melanopsin retinal ganglion cell loss and circadian dysfunction in Alzheimer’s disease (review). Mol Med Rep. 2016;13:3397–400.PubMedPubMedCentralGoogle Scholar
  66. 66.
    La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90–109.CrossRefPubMedGoogle Scholar
  67. 67.
    Dibner C, Schibler U. Circadian timing of metabolism in animal models and humans. J Intern Med. 2015;277:513–27.CrossRefPubMedGoogle Scholar
  68. 68.
    Maury E, Hong HK, Bass J. Circadian disruption in the pathogenesis of metabolic syndrome. Diabetes & Metabolism. 2014;40:338–46.CrossRefGoogle Scholar
  69. 69.
    Weljie AM, Meerlo P, Goel N, et al. Oxalic acid and diacylglycerol 36:3 are cross-species markers of sleep debt. Proc Natl Acad Sci U S A. 2015;112:2569–74.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Davies SK, Ang JE, Revell VL, et al. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A. 2014;111:10761–6.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1:e62.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2016.Google Scholar
  73. 73.
    Willette AA, Bendlin BB, Starks EJ, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA neurology. 2015;72:1013–20.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Luciano R, Barraco GM, Muraca M, et al. Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood. Pediatrics. 2015;135:1074–81.CrossRefPubMedGoogle Scholar
  75. 75.
    Alessi CA, Yoon EJ, Schnelle JF, Al-Samarrai NR, Cruise PA. A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? J Am Geriatr Soc. 1999;47:784–91.CrossRefPubMedGoogle Scholar
  76. 76.
    Graf A, Wallner C, Schubert V, et al. The effects of light therapy on mini-mental state examination scores in demented patients. Biol Psychiatry. 2001;50:725–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Lyketsos CG, Lindell Veiel L, Baker A, Steele C. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. International Journal of Geriatric Psychiatry. 1999;14:520–5.CrossRefPubMedGoogle Scholar
  78. 78.
    Dowling GA, Graf CL, Hubbard EM, Luxenberg JS. Light treatment for neuropsychiatric behaviors in Alzheimer’s disease. West J Nurs Res. 2007;29:961–75.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    • van Maanen A, Meijer AM, van der Heijden KB, Oort FJ. The effects of light therapy on sleep problems: a systematic review and meta-analysis. Sleep Med Rev. 2016;29:52–62. A recent systematic review and meta-analysis looking at the effects of light therapy in circadian rhythm sleep disorders, insomnia, AD, and dementia. Eleven studies included patients with AD/dementia and a total of N = 211 patients, demonstrated significant effects of light therapy in patients with AD/dementia in improving sleep onset latency, total sleep time, time in bed, sleep efficiency, and sleep quality. However, there was no significant improvement seen in wake after sleep onset or early morning awakenings. CrossRefPubMedGoogle Scholar
  80. 80.
    Forbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. Cochrane Database Syst Rev. 2014: Cd003946Google Scholar
  81. 81.
    Rudnitskaya EA, Muraleva NA, Maksimova KY, Kiseleva E, Kolosova NG, Stefanova NA. Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD. 2015;47:103–16.CrossRefPubMedGoogle Scholar
  82. 82.
    Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2003;70:334–41.CrossRefPubMedGoogle Scholar
  83. 83.
    Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–61.PubMedPubMedCentralGoogle Scholar
  84. 84.
    • Wang YY, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang YT. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. International Journal of Geriatric Psychiatry. 2017;32:50–7. A recent meta-analysis looking at the effects of melatonin in AD. Seven studies included patients with AD and a total of N = 462 patients, with the administration of melatonin dosage ranging from 1.5 to 10 mg, from 10 days to 24 weeks, demonstrated that patients receiving melatonin treatment showed prolonged total sleep time at night. Melatonin, however, did not improve cognitive abilities assessed by the mini-mental state examination (MMSE) or the Alzheimer’s Disease Assessment Cognitive Subscale (ADACS). CrossRefPubMedGoogle Scholar
  85. 85.
    Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging. 2007;28:1239–47.CrossRefPubMedGoogle Scholar
  86. 86.
    Dowling GA, Burr RL, Van Someren EJ, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J Am Geriatr Soc. 2008;56:239–46.CrossRefPubMedGoogle Scholar
  87. 87.
    Furuya M, Miyaoka T, Yasuda H, et al. Marked improvement in delirium with ramelteon: five case reports. Psychogeriatrics: the official journal of the Japanese Psychogeriatric Society. 2012;12:259–62.CrossRefGoogle Scholar
  88. 88.
    Ooms S, Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol. 2016;18:40.CrossRefPubMedGoogle Scholar
  89. 89.
    Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. The American Journal of Geriatric Psychiatry: official journal of the American Association for Geriatric Psychiatry. 2014;22:1565–74.CrossRefGoogle Scholar
  90. 90.
    Grippe TC, Goncalves BS, Louzada LL, et al. Circadian rhythm in Alzheimer disease after trazodone use. Chronobiol Int. 2015;32:1311–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of NeurologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations